Form 4: Dexcom Director Bridgette P. Heller Sells 1,000 Shares Under 10b5-1 Plan

Dexcom Inc. Director Bridgette P. Heller sold 1,000 shares of common stock at $70 per share on September 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On September 16, 2024, Bridgette P. Heller, a director of Dexcom Inc., sold 1,000 shares of Dexcom's common stock.
• The sale was executed at a price of $70 per share.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on February 25, 2024.
• Following the transaction, Ms. Heller beneficially owns 24,349 shares of Dexcom common stock, which includes 2,618 unvested restricted stock units.
• These restricted stock units were granted on May 22, 2024, and will vest on the earlier of the one-year anniversary of the grant date or DexCom Inc's 2025 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a routine stock sale by a company director under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates